Literature DB >> 24764148

Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.

Piyanuch Wonganan1, Kristina Jonsson-Schmunk1, Shellie M Callahan1, Jin Huk Choi1, Maria A Croyle2.   

Abstract

HC-04 cells were evaluated as an in vitro model for mechanistic study of changes in the function of hepatic CYP3A during virus infection. Similar to in vivo observations, infection with a first generation recombinant adenovirus significantly inhibited CYP3A4 catalytic activity in an isoform-specific manner. Virus (MOI 100) significantly reduced expression of the retinoid X receptor (RXR) by 30% 96 hours after infection. Cytoplasmic concentrations of the pregnane X receptor (PXR) were reduced by 50%, whereas the amount of the constitutive androstane receptor (CAR) in the nuclear fraction doubled with respect to uninfected controls. Hepatocyte nuclear factor 4α (HNF-4α) and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) were also reduced by ∼70% during infection. Virus suppressed CYP3A4 activity in the presence of the PXR agonist rifampicin and did not affect CYP3A4 activity in the presence of the CAR agonist CITCO [6-(4-chlorophenyl) imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime], suggesting that virus-induced modification of PXR may be responsible for observed changes in hepatic CYP3A4. The HC-04 cell line is easy to maintain, and CYP3A4 in these cells was responsive to known inducers and suppressors. Dexamethasone (200 μM) and phenobarbital (500 μM) increased activity by 230 and 124%, whereas ketoconazole (10 μM) and lipopolysaccharide (LPS) (10 μg/ml) reduced activity by 90 and 92%, respectively. This suggests that HC-04 cells can be a valuable tool for mechanistic study of drug metabolism during infection and for routine toxicological screening of novel compounds prior to use in the clinic.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24764148      PMCID: PMC4053995          DOI: 10.1124/dmd.113.056663

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  59 in total

Review 1.  The role of body-on-a-chip devices in drug and toxicity studies.

Authors:  M B Esch; T L King; M L Shuler
Journal:  Annu Rev Biomed Eng       Date:  2011-08-15       Impact factor: 9.590

2.  Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04.

Authors:  Priscilla L K Lim; Weiqi Tan; Calivarathan Latchoumycandane; Wei Chuen Mok; Yok Moi Khoo; How Sung Lee; Jetsumon Sattabongkot; Walter Beerheide; Seng Gee Lim; Theresa M C Tan; Urs A Boelsterli
Journal:  Toxicol In Vitro       Date:  2007-05-17       Impact factor: 3.500

Review 3.  Retinoid X receptors: common heterodimerization partners with distinct functions.

Authors:  Philippe Lefebvre; Yacir Benomar; Bart Staels
Journal:  Trends Endocrinol Metab       Date:  2010-07-30       Impact factor: 12.015

4.  Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes.

Authors:  N Milosevic; H Schawalder; P Maier
Journal:  Eur J Pharmacol       Date:  1999-02-26       Impact factor: 4.432

Review 5.  Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes.

Authors:  Julius Brtko; Zdenek Dvorak
Journal:  Curr Drug Metab       Date:  2011-02       Impact factor: 3.731

Review 6.  Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond.

Authors:  Xiaojuan Chai; Su Zeng; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-01-17       Impact factor: 4.481

7.  The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.

Authors:  Rommel G Tirona; Wooin Lee; Brenda F Leake; Lu-Bin Lan; Cynthia Brimer Cline; Vishal Lamba; Fereshteh Parviz; Stephen A Duncan; Yusuke Inoue; Frank J Gonzalez; Erin G Schuetz; Richard B Kim
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

Review 8.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

Review 9.  The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Authors:  Tommy B Andersson; Kajsa P Kanebratt; John Gerry Kenna
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-05-08       Impact factor: 4.481

10.  Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation.

Authors:  Romi Ghose; Tracy L Zimmerman; Sundararajah Thevananther; Saul J Karpen
Journal:  Nucl Recept       Date:  2004-08-16
View more
  3 in total

1.  Integrin Receptors Play a Key Role in the Regulation of Hepatic CYP3A.

Authors:  Kristina Jonsson-Schmunk; Piynauch Wonganan; Jin Huk Choi; Shellie M Callahan; Maria A Croyle
Journal:  Drug Metab Dispos       Date:  2016-02-11       Impact factor: 3.922

2.  Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.

Authors:  Kristina Jonsson-Schmunk; Romi Ghose; Maria A Croyle
Journal:  Expert Rev Vaccines       Date:  2021-03-18       Impact factor: 5.217

Review 3.  The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy.

Authors:  Guyi Wang; Bing Xiao; Jiayi Deng; Linmei Gong; Yi Li; Jinxiu Li; Yanjun Zhong
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.